Last reviewed · How we verify
NCT06170619: OCCLUDE
Obsidio™ Conformable Embolic Registry
trial testing Obsidio™ Conformable Embolic in Hypervascular Tumors in 125 participants. Completed in 9 September 2025.
9 September 2025
Quick facts
| Lead sponsor | Boston Scientific Corporation |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 125 |
| Start date | 19 June 2024 |
| Primary completion | 9 September 2025 |
| Estimated completion | 9 September 2025 |
| Sites | 20 locations across United States |
Drugs / interventions tested
- Obsidio™ Conformable Embolic
Conditions studied
- Hypervascular Tumors — all drugs for Hypervascular Tumors →
- Bleeding — all drugs for Bleeding →
- Hemorrhage — all drugs for Hemorrhage →
Sponsor
Boston Scientific Corporation — full company profile →
Who can join
18 and older, any sex, with Hypervascular Tumors or Bleeding. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
OCCLUDE is a prospective, post-approval, open-label, single arm, multi-center US registry of patients who undergo embolization with Obsidio™ Conformable Embolic. The purpose of this Registry is to assess effectiveness and safety outcomes of subjects who undergo embolization with Obsidio.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06170619
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Boston Scientific Corporation trials
Trials by the same sponsor.
- NCT07458243 — Registry of ENROUTE NPS in Conjunction With Carotid WALLSTENT · not yet recruiting
- NCT07458217 — Combined CM and STN Stimulation for Motor Epilepsy · NA · not yet recruiting
- NCT07276815 — OverStitch NXT Endoscopic Suture System · NA · not yet recruiting
- NCT07353710 — A Study on the Acquisition of 2D ICE Images With the CHORUS IDx System in Subjects Undergoing an Ablation Procedure · NA · not yet recruiting
- NCT07195708 — Orbera365 Intragastric Balloon System (Abbreviated as'Orbera365') · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06170619 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Boston Scientific Corporation
- Last refreshed: 17 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06170619.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing